N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, Do KQ
Published in Schizophrenia Bulletin
Key Findings
Six months of NAC 2.7 g/d increased brain glutathione levels measured by magnetic resonance spectroscopy but did not improve the primary positive symptom outcome.
Conclusions
NAC raises central glutathione, yet clinical benefit was limited to secondary cognitive measures.
Limitations
Modest sample, single primary endpoint negative, subgroup-dependent effects.
Supplements Studied
Six months of NAC 2.7 g/d increased brain glutathione levels measured by magnetic resonance spectroscopy.
Six months of NAC 2.7 g/d increased brain glutathione levels measured by magnetic resonance spectroscopy but did not improve the primary positive symptom outcome.
Outcomes Measured
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.